Clinical Trial Results:
Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis®
(PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing
Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy.
Étude de phase II , multicentrique, ouverte, clinique et pharmacocinétique de Zalypsis® (PM00104) chez des patients atteints d’un sarcome de la famille des tumeurs d’Ewing (EFT) non resécable, localement avancé et/ou métastatique en progression après au moins une première ligne chimiothérapique
Summary
|
|
EudraCT number |
2010-022221-15 |
Trial protocol |
FR IT |
Global completion date |
24 Apr 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Aug 2016
|
First version publication date |
05 Aug 2016
|
Other versions |
|
Summary report(s) |
2010-022221-15 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.